Article Text

other Versions

Download PDFPDF
COVID-19 and gynecological cancer: a review of the published guidelines
  1. Christina Uwins1,
  2. Geetu Prakash Bhandoria2,
  3. TS Shylasree3,
  4. Simon Butler-Manuel1,
  5. Patricia Ellis1,
  6. Jayanta Chatterjee1,
  7. Anil Tailor1,
  8. Alexandra Stewart4 and
  9. Agnieszka Michael5
  1. 1 Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Guildford, United Kingdom
  2. 2 Obstetrics & Gynecology Oncology, Command Hospital, Pune, Maharashtra, India
  3. 3 Department of Gynaecologic Oncology, Tata Memorial Hospital, Homi Baba National Institute, Mumbai, India
  4. 4 St Luke’s Cancer Centre, Department of Oncology, Royal Surrey NHS Foundation Trust, Guildford, United Kingdom
  5. 5 Department of Oncology, University of Surrey, Guildford, United Kingdom
  1. Correspondence to Dr Geetu Prakash Bhandoria, Obstetrics & Gynecology, Command Hospital Pune, Pune 411040, Maharashtra, India; doctor_071277{at}


On March 11, 2020 the COVID-19 outbreak was declared a ‘pandemic’ by the World Health Organization. COVID-19 is associated with higher surgical morbidity and mortality. An array of guidelines on the management of cancer during this pandemic have been published since the first reports of the outbreak. This narrative review brings all the relevant information from the guidelines together into one document, to support patient care. We present a detailed review of published guidelines, statements, comments from peer-reviewed journals, and nationally/internationally recognized professional bodies and societies' web pages (in English or with English translation available) between December 1, 2019 and May 27, 2020. Search terms included combinations of COVID, SARS-COV-2, guideline, gynecology, oncology, gynecological, cancer. Recommendations for surgical and oncological prioritization of gynecological cancers are discussed and summarized. The role of minimally invasive surgery, patient perspectives, medico-legal aspects, and clinical trials during the pandemic are also discussed. The consensus is that elective benign surgery should cease and cancer surgery, chemotherapy, and radiotherapy should continue based on prioritization. Patient and staff face-to-face interactions should be limited, and health resources used efficiently using prioritization strategies. This review and the guidelines on which it is based support the difficult decisions currently facing us in gynecological cancer. It is a balancing act: limited resources and a hostile environment pitted against the time-sensitive nature of cancer treatment. We can only hope to do our best for our patients with the resources available to us.

  • gynecology
  • carcinoma
  • gynecologic surgical procedures
  • radiotherapy

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @Bhandoria

  • Contributors Study concepts and design: SS, GPB, CU. Data acquisition: CU, GPB. Manuscript preparation: All authors. Manuscript editing: All authors. All authors read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests SB-M: Proctor for Intuitive Surgical and Plasma Surgical and Ethicon. JC: Occasionally gives paid lectures on behalf of pharmaceutical companies. AS: Honorarium from Elekta. AM: Educational grants from Clovis, GSK, Ipsen, Novartis, Pfizer, and Tesaro.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.